Review of clinical studies of perampanel in adolescent patients

被引：11

作者：

Kim, Heung Dong ^{[1
]}

Chi, Ching-Shiang ^{[2
]}

Desudchit, Tayard ^{[3
]}

Nikanorova, Marina ^{[4
]}

Visudtibhan, Anannit ^{[5
]}

Nabangchang, Charcrin ^{[6
]}

Chan, Derrick W. S. ^{[7
]}

Fong, Choong Yi ^{[8
]}

Chang, Kai-Ping ^{[9
]}

Kwan, Shang-Yeong ^{[10
]}

De Los Reyes, Fe ^{[11
]}

Huang, Chao-Ching ^{[12
]}

Likasitwattanakul, Surachai ^{[13
]}

Lee, Wang-Tso ^{[14
]}

Yung, Ada ^{[15
]}

Dash, Amitabh ^{[16
]}

机构：

[1] Yonsei Univ, Div Pediat Neurol, Severance Childrens Hosp, Seoul, South Korea

[2] Tungs Taichung Metro Harbor Hosp, Dept Pediat, Taichung, Taiwan

[3] King Chulalongkorn Mem Hosp, Dept Paediat Neurol, Bangkok, Thailand

[4] Danish Epilepsy Ctr Filadelfia, Childrens Dept, Dianalund, Denmark

[5] Mahidol Univ, Div Neurol, Dept Pediat, Fac Med,Ramathibodi Hosp, Bangkok, Thailand

[6] Phramongkutklao Hosp, Dept Paediat, Bangkok, Thailand

[7] KK Womens & Childrens Hosp, Dept Paediat, Singapore, Singapore

[8] Univ Malaya, Div Paediat Neurol, Dept Paediat, Fac Med, Kuala Lumpur, Malaysia

[9] Taipei Vet Gen Hosp, Dept Pediat, Taipei, Taiwan

[10] Taipei Vet Gen Hosp, Dept Neurol, Taipei, Taiwan

[11] Mother Seton Hosp, Dept Pediat, Camarines Sur, Philippines

[12] Taipei Med Univ, Dept Pediat, Coll Med, Taipei, Taiwan

[13] Mahidol Univ, Dept Pediat, Fac Med, Siriraj Hosp, Bangkok, Thailand

[14] Natl Taiwan Univ Hosp, Dept Pediat, Taipei, Taiwan

[15] Duchess Kent Childrens Hosp, Dept Pediat, Sandy Bay, Hong Kong, Peoples R China

[16] Eisai Pharmaceut India Pvt Ltd, Bombay, Maharashtra, India

来源：

BRAIN AND BEHAVIOR | 2016年 / 6卷 / 09期

关键词：

Adolescent; Anticonvulsants; consensus; epilepsy; perampanel; receptors AMPA; PARTIAL-ONSET SEIZURES; RANDOMIZED PHASE-III; ADJUNCTIVE PERAMPANEL; RECEPTOR ANTAGONIST;

D O I：

10.1002/brb3.505

中图分类号：

B84 [心理学]; C [社会科学总论]; Q98 [人类学];

学科分类号：

03 ; 0303 ; 030303 ; 04 ; 0402 ;

摘要：

Aim: To assess the clinical trial and real-world data for adjunctive perampanel in adolescents and develop consensus recommendations to guide the use of perampanel in this population in clinical practice. Methods: In May 2015, 15 epilepsy experts attended a Consensus Development Meeting to assess the clinical trial data for perampanel, specific to the adolescent age group (12-17 years) and develop consensus treatment recommendations. Results and Discussion: Analysis of the adolescent subgroup data of three pivotal placebo-controlled, double-blind, phase 3 trials investigating perampanel in patients with ongoing focal epileptic seizures despite receiving one to three antiepileptic drugs found that perampanel 4-12 mg was superior to placebo. The tolerability profile of perampanel was generally acceptable. Adolescent patients receiving long-term treatment with perampanel in an open-label extension study maintained improvements in seizure control compared with baseline, with a favorable risk-benefit profile. A phase 2 study showed that perampanel had no clinically important effects on cognitive function, growth, and development. Conclusion: Perampanel is a welcome addition to the armamentarium of existing antiepileptic drugs as it represents a new approach in the management of epilepsy, with a novel mechanism of action, and the potential to have a considerable impact on the treatment of adolescents with epilepsy.

引用

页数：9

共 17 条

[1]

[Anonymous], 2010, CDC Growth Charts

[2] Effectiveness and Tolerability of Perampanel in Children and Adolescents with Refractory Epilepsies: First Experiences [J].